free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Lupin gets US FDA approval for Colesevelam Hydrochloride Tablets

expresspharmaDecember 21, 2020

Tag: lupin , FDA , LDL-C , Colesevelam Hydrochloride Tablets , Welchol

Lupin has received approval for its Colesevelam Hydrochloride Tablets, 625 mg, from the United States Food and Drug Administration (US FDA), to market a generic equivalent of Welchol Tablets, 625 mg, of Daiichi Sankyo. Colesevelam Hydrochloride Tablets, 625 mg, are indicated as an adjunct to diet and exercise to:

  • reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.

  • reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH).

Colesevelam Hydrochloride Tablets (RLD: Welchol) had an annual sales of approximately $159 million in the US (IQVIA MAT September 2020).


Previous:DoP submits revised PTUAS scheme document to Expenditure Finance Committee

Next:Strides gets USFDA nod for Oxybutynin Chloride Tablets

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service